Multiple Myeloma
Conditions
Keywords
haploidentical hematopoietic stem cell transplantation (haploHSCT), registry
Brief summary
The goal of this observational study is to register hematologic patients with haploidentical hematopoietic stem cell transplantation (haploHSCT). The main questions it aims to answer are: * 1-year progression free survival rate * 1-year overall survival rate * Graft-versus-host free relapsed free survival at 30-day, 100-day, 180-day and 1-year * Chronic Graft-versus-host free relapsed free survival at 180-day and 1-year * Rate of Neutrophil and platelet engraftment * Efficacy of donor specific antibody desensitization * Relapsed rate * Primary and late graft failure * Safety and complication of haploHSCT * Complication of viral, bacterial, and fungal infection * Viral reactivation * Comparison outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT * Comparison cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
Interventions
None listed
Sponsors
Siriraj Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with hematologic diseases indicated for treatment with haploidentical hematopoietic stem cell transplantation including 1. Myeloid diseases (acute myeloblastic leukemia, myelodysplastic syndrome, chronic myelocytic leukemia, classical and non-classical myeloproliferative disorders) 2. Lymphoid disease (acute lymphoblastic leukemia, lymphoma) 3. severe aplastic anemia * Unable to find a matched sibling donor (MSD) or matched unrelated donor (MUD), and no alternative treatments * Eastern Cooperative Oncology Group (ECOG) 0-2 * normal AST and ALT, creatinine <2g/dL, and left ventricular ejection fraction ≥50% * age >18 years * Capable of informed consent and provision of written informed consent before any study procedures * Capable of attending all study visits according to the study schedule * Female subjects who is childbearing potential must have a negative result for pregnancy test
Exclusion criteria
* HIV infection, active hepatitis B, active hepatitis C * active infection * history of other malignancy except basal cell carcinoma and carcinoma of the cervix in situ * A pregnant woman and/or refusal of contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| register hematologic patients with haploidentical hematopoietic stem cell transplantation | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| overall survival rate | 1 year |
| Chronic Graft-versus-host free relapsed free survival | at 180-day and 1-year |
| Relapsed rate | 5 years |
| Primary and late graft failure | 5 years |
| Rate of Neutrophil and platelet engraftment | during admission |
| progression free survival rate | 1 year |
| Safety and complication of haploHSCT | 5 years |
| Complication of viral, bacterial, and fungal infection | during admission |
| Viral reactivation | during admission |
| outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT | 5 years |
| cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT | 5 years |
| Efficacy of donor specific antibody desensitization | during admission |
Contacts
Primary ContactChutima Kunacheewa, MD
Backup ContactWeerapat Owatthanapanich, MD
Outcome results
None listed